Yumanity chairman Tony Coles (L) and CEO Richard Peters
August 29, 2022 11:37 AM EDTUpdated 01:19 PM
Deals

Af­ter clin­i­cal hold quashed its hopes, Yu­man­i­ty field­ed 10 bid­ders be­fore land­ing on two-way deal with J&J, Kine­ta

Amber Tong

What sends a biotech down the dread­ed jour­ney of ex­plor­ing “strate­gic al­ter­na­tives”?

In the case of Yu­man­i­ty, af­ter steadi­ly los­ing its val­ue since a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

A service from the Financial Times